11/06/2025
📢 🇬🇧 DELGOCITINIB ACCESS EXPANDED: The National Institute for Health and Care Excellence (NICE) has recommended reimbursement of delgocitinib cream for adult patients with moderate to severe chronic hand eczema (CHE) in England and Wales. Citing data from the DELTA trials, the decision expands the options for patients with limited response to corticosteroids and underscores the need for equitable assessment across diverse skin tones.
Read more ➡️ https://ow.ly/CRiE50Xo5lw